Healthcare & Medical Devices Global On demand · 24-48h

Global Hyperthermia Therapy for Cancer Market Strategic Research Report

Global Hyperthermia Therapy for Cancer Market Strategic Rese…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Hyperthermia Therapy for Cancer Market
$4392025
5.7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Superficial Hyperthermia, Deep Regional Hyperthermia

By Application: Breast Cancer, Cervical Cancer, Soft Tissue Sarcoma, Melanoma, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Pyrexar Medical, Oncotherm, Andromedic, Yamamoto Vinita, Med-Logix, Thermofield, Celsius42, Dongseo Medicare, ThermaSolutions, Verthermia, Combat Medical, Hydrosun, RanD Biotech, Shenzhen ET Medical Technology, Jiangsu Nova Medical Equipment

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 112 pages
Market size 2025
$439
Million USD
Forecast CAGR
5.7%
2025-2032
Forecast 2032
$647.1
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Hyperthermia Therapy for Cancer market size is predicted to grow from US$ 439 million in 2025 to US$ 643 million in 2032; it is expected to grow at a CAGR of 5.7% from 2026 to 2032.

Hyperthermia therapy for cancer, also known as thermal therapy or thermotherapy, is a type of treatment in which body tissue is exposed to high temperatures (up to 113°F or 45°C) to damage and kill cancer cells. This approach can enhance the effectiveness of other treatments such as radiation therapy and chemotherapy. Hyperthermia is typically used to treat tumors located in specific parts of the body, such as the chest, liver, or limbs. The heat can be applied using various techniques, including external applicators, internal probes, or perfusion methods where heated substances are circulated through the body. The primary goal is to target cancer cells while minimizing damage to surrounding healthy tissue.

The hyperthermia therapy for cancer market is witnessing growing interest due to its potential to enhance the effectiveness of conventional cancer treatments such as radiation and chemotherapy. As a non-invasive or minimally invasive technique, hyperthermia therapy appeals to both clinicians and patients seeking targeted therapeutic options with fewer systemic side effects. Technological advancements in thermal delivery systems and imaging-guided precision are further improving clinical outcomes and driving innovation. Although still considered an adjunct treatment in many oncology protocols, the increasing number of clinical studies and expanding awareness of its benefits suggest that hyperthermia therapy is poised to become a more integral component of comprehensive cancer care strategies in the coming years.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hyperthermia Therapy for Cancer market?

What factors are driving Hyperthermia Therapy for Cancer market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Hyperthermia Therapy for Cancer market opportunities vary by end market size?

How does Hyperthermia Therapy for Cancer break out by Type, by Application?

This report presents a comprehensive overview of the global Hyperthermia Therapy for Cancer market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Superficial Hyperthermia
  • Deep Regional Hyperthermia

Segment by Application

  • Breast Cancer
  • Cervical Cancer
  • Soft Tissue Sarcoma
  • Melanoma
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Hyperthermia Therapy for Cancer market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Breast Cancer, Cervical Cancer, Soft Tissue Sarcoma evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Hyperthermia Therapy for Cancer Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$439
2025
Forecast
$647.1
2032
CAGR
5.7%
2025–2032
Regions
5
global
Key companies
Pyrexar MedicalOncothermAndromedicYamamoto VinitaMed-LogixThermofieldCelsius42Dongseo Medicare
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Superficial HyperthermiaDeep Regional Hyperthermia
By Application
Breast CancerCervical CancerSoft Tissue SarcomaMelanomaOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Superficial Hyperthermia
  • 3.1.3 Deep Regional Hyperthermia
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Breast Cancer
  • 4.1.3 Cervical Cancer
  • 4.1.4 Soft Tissue Sarcoma
  • 4.1.5 Melanoma
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Pyrexar Medical
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Oncotherm
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Andromedic
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Yamamoto Vinita
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Med-Logix
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Thermofield
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Celsius42
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Dongseo Medicare
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 ThermaSolutions
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Verthermia
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Combat Medical
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Hydrosun
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 RanD Biotech
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Shenzhen ET Medical Technology
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Jiangsu Nova Medical Equipment
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Hyperthermia Therapy for Cancer market size?
The global Hyperthermia Therapy for Cancer market is estimated at US$ 439 million in 2025 (base year) and is projected to reach US$ 643 million by 2032.
What growth rate is expected for the Hyperthermia Therapy for Cancer market through 2032?
The market is expected to grow at a CAGR of 5.7% from 2026 to 2032, expanding from US$ 439 million in 2025 to US$ 643 million in 2032, roughly 1.5 times its base-year value.
How is Hyperthermia Therapy for Cancer defined?
Hyperthermia therapy for cancer, also known as thermal therapy or thermotherapy, is a type of treatment in which body tissue is exposed to high temperatures (up to 113°F or 45°C) to damage and kill cancer cells. This approach can enhance the effectiveness of other treatments such as radiation therapy and chemotherapy. Hyperthermia is typically used to treat tumors located in specific parts of the body, such as the chest, liver, or limbs.
What are the main segments of the Hyperthermia Therapy for Cancer market by type?
By type, the market is segmented into Superficial Hyperthermia and Deep Regional Hyperthermia.
Which applications drive demand in the Hyperthermia Therapy for Cancer market?
Key applications covered include Breast Cancer, Cervical Cancer, Soft Tissue Sarcoma, Melanoma and Others.
Who are the key players in the Hyperthermia Therapy for Cancer market?
Key players profiled include Pyrexar Medical, Oncotherm, Andromedic, Yamamoto Vinita, Med-Logix, Thermofield, Celsius42 and Dongseo Medicare, among 15 companies covered in total.
Which regions and countries are covered for Hyperthermia Therapy for Cancer?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Hyperthermia Therapy for Cancer market?
Technological advancements in thermal delivery systems and imaging-guided precision are further improving clinical outcomes and driving innovation.
Who should buy the Hyperthermia Therapy for Cancer market report?
The report is intended for manufacturers and solution providers, distributors and end users in Breast Cancer, Cervical Cancer and Soft Tissue Sarcoma, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Hyperthermia Therapy for Cancer market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.